drugset / Trial / NCT07412262
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
Phase 2
Not yet recruiting
32 enrolled
Guangdong Association of Clinical Trials
Akesobio · collabInnovent Biologics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of Chidamide in combination with Ivonescimab in the treatment of advanced non-small cell lung cancer with secondary immune resistance and high YAP protein expression.
Timeline
- Start
- 2026-05-15
- Primary completion
- 2028-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |